Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 4/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 4/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27357474 | 0.80 | GAA (0.41) | MGAMGAASIMGAM2CES2 | |
| SCHEMBL20305724 | 0.79 | ALDH1A1 (0.46) | CYP4F2CYP4A11MGAMGAASI | |
| SCHEMBL243267 | 0.79 | ALDH1A1 (0.46) | CYP4F2CYP4A11MGAMGAASI | |
| SCHEMBL23636447 | 0.79 | ALDH1A1 (0.46) | CYP4F2CYP4A11MGAMGAASI | |
| SCHEMBL5691531 | 0.79 | ALDH1A1 (0.46) | CYP4F2CYP4A11MGAMGAASI | |
| SCHEMBL23636486 | 0.79 | ALDH1A1 (0.46) | CYP4F2CYP4A11MGAMGAASI | |
| SCHEMBL1401418 | 0.79 | ALDH1A1 (0.46) | CYP4F2CYP4A11MGAMGAASI | |
| SCHEMBL6665142 | 0.79 | GAA (0.52) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL21069035 | 0.79 | CYP4F2 (0.38) | CYP4F2CYP4A11MGAMGAASI | |
| SCHEMBL21069076 | 0.78 | PPID (0.41) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| CN-111491623-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | ASTRAZENECA PHARMACEUTICALS LP | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194190-A1 | Compounds and Their Use in Treating Cancer | F12, CCNY, CCNE1 | CYP4F2 107/4885CYP4A11 355/4885MGAM 2541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.